Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations of BRCA1, BRCA2, and PALB2 Genes in Breast Tumor Tissue: Relationship with the Effectiveness of Neoadjuvant Chemotherapy and Disease Prognosis.

Genes - 28 Jul 2023

Tsyganov Matvey M, Sorokovikova Sofia S, Lutzkaya Elizaveta A, Ibragimova Marina K

Abstract excerpt

It has been shown that the loss of function of the BRCA1, BRCA2, and PALB2 genes due to a number of hereditary mutations or chromosomal aberrations can affect the effectiveness of chemotherapy treatment and disease prognosis in patients with various types of cancer, and in particular in breast cancer. Thus, the aim of the work was to evaluate the predictive and prognostic potential of DNA copy number aberrations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Chromosome Aberrations

Share to Fanconi Anemia Complementation Group N Protein

Share to Genes, BRCA2

Share to Neoadjuvant Therapy

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 37628606
DOI: 10.3390/genes14081554
PMCID: PMC10454606

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations of BRCA1, BRCA2, and PALB2 Genes in Breast Tumor Tissue: Relationship with the Effectiveness of Neoadjuvant Chemotherapy and Disease Prognosis.PMID 37628606Read ↗

Prediction of Specific Survival and Clinicopathological Impact of Somatic PALB2 Mutations and Pathogenic/Likely Pathogenic Variants (PV/LPV) in Breast Cancer: A Cohort Study of 81 Patients.Semantic proximity Read ↗

The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers.Semantic proximity Read ↗

Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.Semantic proximity Read ↗

Effect of PALB2 status on breast cancer precision medicine.Semantic proximity Read ↗

BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.Semantic proximity Read ↗

Next-Generation Sequencing of Breast Cancer in the Neoadjuvant Setting.Semantic proximity Read ↗

Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor typesSemantic proximity Read ↗

BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.Semantic proximity Read ↗

Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression.Semantic proximity Read ↗

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes.Semantic proximity Read ↗

Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapySemantic proximity Read ↗

The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.